Navigation Links
PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma
Date:6/14/2016

MADRID, June 14, 2016 /PRNewswire/ --

PharmaMar (MCE:PHM) today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. As this is classified as a rare disease, and in consultation with the US Food and Drug Administration (FDA), the study has been designed with only one study arm.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

The primary objective is to analyze the efficacy of plitidepsin in terms of overall response rate, to be evaluated by an independent committee following the Lugano classification response criteria. The secondary endpoint will be to evaluate other efficacy parameters such as duration of response, progression free survival and overall survival; the pharmacokinetic characteristics, the safety profile of plitidepsina and the identification of possible biomarkers that help to identify the predictive activity of the compound.

"This pivotal clinical trial will include 60 patients from approximately 25 investigative sites," stated Dr Arturo Soto, Director of Clinical Development at PharmaMar's Oncology Unit . "After the recent announcement of the positive results obtained with plitidepsin in patients with multiple myeloma, we are continuing with the development of this molecule in other hematological tumors such as angioimmunoblastic T-cell lymphoma."

Media Relations: 638-79-62-15

Investor Relations: 914444500


'/>"/>
SOURCE PharmaMar
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. PharmaMar annuncia al Congresso ASCO i risultati positivi dello studio di Fase I della plitidepsina in combinazione con bortezomib e desametasone in pazienti affetti da mieloma multiplo
2. PharmaMar to Present Data on Anticancer Candidates PM1183 and plitidepsin at the AACR Annual Meeting 2015
3. IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
4. PBI-Gordon Announces 2(ee) Recommendation for Surge® Doveweed Control
5. ImMAGE Biotherapeutics Announces Positive Results from In Vitro Trials
6. Seton Hall Law Announces Health Law LL.M. Degree Program Now Available Online
7. Cambrian Innovation Announces Pilot of Self-Powered Water Treatment System with U.S. Army
8. Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
9. zPREDICTA Announces Revolutionary Cancer Drug Testing Platform
10. Keck Graduate Institute School of Pharmacy Announces 2016 White Coat Ceremony Speaker
11. Global Stem Cells Group Announces Launch of Operations in Arica and Iquique, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):